Abstract
Hematopoietic stem cells maintain life long blood generation during homeostasis and stress. Factors controlling the key characteristics of these cells such as self-renewal, quiescence and the potential to form various blood lineages are poorly understood. We reasoned that genes found to be located near common sites of vector insertion in clinical gene therapy studies might have important functions in this regard. The DNA binding protein, high mobility Group AT hook 2 (HMGA2) is one such factor. HMGA2 activation coupled with a myeloid biased clonal dominance of stem/progenitor cells was observed in a clinical gene therapy trial for β-thalassemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
